

Correction: *EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update*

Smolen JS, Landewé RBM, Bergstra SA, *et al.* EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. *Ann Rheum Dis* 2023;82:3–18.

The competing interests statement was erroneously omitted and is now included. This correction has not been made in print.

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.

Ann Rheum Dis 2023;82:e76. doi:10.1136/ard-2022-223356corr1

